Imaging Biometrics (IB) announced the publication of a review about the use of advanced MRI techniques in Europe, acknowledging the limitations and challenges presented with conventional MRI.
The paper, published in Frontiers in Oncologya, was written by an international team of clinicians, engineers, and physicists working on behalf of the European Cooperation in Science and Technology (COST) Glioma MR Imaging 2.0 (GLiMR) Initiative.
It consisted of a comprehensive review of advanced MRI techniques used for monitoring treatment response in high-grade brain tumors currently practiced in Europe, which included use of Imaging Biometrics’ solutions. The authors of the study concluded that dynamic susceptibility contrast (DSC) MRI is the most proven of all advanced methods. Imaging Biometrics’ software modules, IB NeuroTM and IB DCETM, provide solutions for analysis of this data, with examples from each included in the paper.
The study acknowledged the limitations and challenges presented with conventional MRI and specifically noted the quantitative technology contained in IB Neuro termed “standardization”. This exclusive technology is built into IB Neuro and automatically generates standardized relative cerebral blood volume (sRCBV) maps. And, as the paper cites, IB Neuro’s sRCBV has demonstrated greater consistency and improved repeatability over inherently variable and manual “tissue normalization” approaches.
“Standardization is significant because it allows for direct comparison between scans independent of MR scanner platform, field strength, or patient,” says Michael Schmainda, CEO of Imaging Biometrics. “This paper nicely summarizes the advancements made over the years in advanced MRI techniques, and we are pleased that the sRCBV technology available in IB Neuro was highlighted.”
